Oxaliplatin-induced Hypersensitivity Reaction- A Rare Reaction in a Patient with Rectal Cancer on Chemotherapy

Full Article - PDF

Published: 2022-07-08

Page: 68-70


Nisarg R. Hajariwala *

Department of Clinical Pharmacy, HCG Cancer Center, Vadodara, India.

Aayush Gandhi

Department of Clinical Pharmacy, HCG Cancer Center, Vadodara, India.

Pinaki Mahato

Department of Medical Oncology, HCG Cancer Center, Vadodara, India.

*Author to whom correspondence should be addressed.


Abstract

Oxaliplatin is a third-generation platinum compound, used in combination with fluoropyrimidine, is indicated for - adjuvant treatment of stage III colorectal cancer (CRC) in patients who have undergone complete resection of the primary tumor and in treatment of advanced colorectal cancer. Nausea, fatigue, anemia, vomiting, diarrhea, increased liver enzymes, peripheral neuropathy, and stomatitis are the common side effects. Serious adverse effects such as - thrombocytopenia, neutropenia, hypersensitivity, etc are also observed. A case of oxaliplatin-induced hypersensitivity reaction in a patient with rectal cancer is described in this article. The patient was prescribed injection oxaliplatin 150mg for chemotherapy treatment along with irinotecan and 5 fluorouracil (FOLFIRINOX regimen). This was the 8th cycle of the same regimen. The patient developed hypersensitivity during the treatment and the drug was withdrawn and the patient was treated for a hypersensitivity reaction. This case report illustrates oxaliplatin-induced hypersensitivity reaction - a rare and serious reaction in a patient with rectal cancer on chemotherapy.

Keywords: Oxaliplatin, colorectal cancer, folfirinox, hypersensitivity reaction


How to Cite

Hajariwala, N. R., Gandhi, A., & Mahato, P. (2022). Oxaliplatin-induced Hypersensitivity Reaction- A Rare Reaction in a Patient with Rectal Cancer on Chemotherapy. Asian Journal of Medical Case Reports, 4(1), 68–70. Retrieved from https://globalpresshub.com/index.php/AJMCR/article/view/1627

Downloads

Download data is not yet available.

References

Oxaliplatin. (n.d.). Retrieved May 25, 2021, from 1Mg.com website: https://www.1mg.com/generics/oxaliplatin-210436

Kolathu S, Lekshmi S, Pillai R, Pavithran K, Neethu CM. Oxaliplatin-induced laryngospasm -A case report. Natl J Physiol Pharm Pharmacol. 2018;8(1):146-148.

Why causality assessment. (n.d.). The use of the WHO-UMC system for standardized case causality assessment.

Retrieved May 25, 2021, from Who. int website: https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf

Hajariwala NR, Chandrakar VR, Lakhani JD. Peripheral neuropathy: A rare side effect of metronidazole. J Integr Health Sci. 2020;8:83-5.

Rothenberg ML. Efficacy of oxaliplatin in the treatment of colorectal cancer. Oncology (Williston Park, N.Y.). 2000;14(12 Suppl 11):9–14.

UpToDate. (n.d.). Retrieved May 28, 2021, from Uptodate.com website: https://www.uptodate.com/contents/infusion-reactions-to-systemic-chemotherapy

Aroldi F, Prochilo T, Bertocchi P, Zaniboni A. Oxaliplatin-induced hypersensitivity reaction: underlying mechanisms and management. Journal of Chemotherapy (Florence, Italy). 2015; 27(2):63–66.